The Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE)

The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:

• What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over?
• What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?

Study Overview

• Status: Recruiting
• Conditions: Cognitive Impairment; Frailty; Disability; Ageing; Intrinsic Capacity

Detailed Description

BLINDSCE is a community-based prospective cohort study that includes individuals aged 65 and over from urban and rural areas in Beijing. Participants will provide detailed demographic information and undergo multifactorial questionnaires, disability measurements, cognitive assessments, other disability-related outcomes, and clinical biochemical measures. The study has started recruitment and enrollment in 2023 and will follow-up once every 1-2 year. This work consists of three steps as follows. First, by collecting baseline and follow-up data of participants, we plan to establish a community-dwelling elderly database in Beijing. Second, high-risk factors can be pre-screening based on this cross-sectional analysis. Third, longitudinal data was used to develop the prediction model and trajectory analysis for disability and cognitive impairment.

• Study Type: Observational
• Enrollment (Estimated): 1962

Contacts and Locations

• Study Contact: Name: Yansu Guo, Ph.D; Phone Number: 0086031183973736; Email: gys188@163.com

Study Locations

• China
  • Beijing, China, 100053
    • Recruiting
    • Xuanwu Hospital, Capital Medical University
    • Contact: Yansu Guo, Ph.D; Phone Number: 0086031183973736; Email: gys188@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Community residents aged 65 years or older in Beijing

Description

Inclusion Criteria:

• Community-dwelling adults aged 65 years or older who reside in Beijing.
• Participants who sign an institutionally approved informed consent.

Exclusion Criteria:

• Participants with severe mental disorders and serious medical conditions preventing study investigation
• Participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disability from the individual's perspective	Disability is assessed using the 12-item World Health Organization's Disability Assessment Schedule 2.0 (WHODAS 2.0). The WHODAS 2.0 is a patient-reported disability measure, comprising six life domains involving cognition, mobility, self-care, interpersonal relationships, life activities, and participation. The total score of 12-item WHODAS 2.0 categorizes disability from no disability (score 0) to complete disability (score 48).	An average of 1 to 2 years
Disability from the medical's perspective	Disability is assessed using the basic activities of daily living (BADL) scale, the Katz Index scale. The minimum value is 0 , and the maximum value is 6. The higher the score, the better the outcome.	An average of 1 to 2 years
Disability from the medical's perspective	Disability is assessed using the instrumental activities of daily living (IADL) scale, the Lawton and Brody IADL scale. The minimum value is 0, and the maximum value is 8. The higher the score, the better the outcome.	An average of 1 to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognitive impairment	The cognitive impairment is assessed by the Mini-Mental State Examination (MMSE). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.	An average of 1 to 2 years
Cognitive impairment	The cognitive impairment is assessed by the Montreal Cognitive Assessment-Basic (MoCA-B). The minimum value is 0, and the maximum value is 30. The higher the score, the better the outcome.	An average of 1 to 2 years
Subjective cognitive decline	Subjective cognitive decline is assessed by the subjective cognitive decline questionnaire-9 items (SCD9). The minimum value of SCD9 is 0, and the maximum value is 9, the higher the score, the worse the outcome.	An average of 1 to 2 years
Intrinsic capacity	Intrinsic capacity is the composite of physical and mental abilities that an individual can draw upon. It comprises locomotor, sensory (hearing and vision), vitality, psychological, and cognition domains. The intrinsic capacity composite score is used to assess intrinsic capacity. The intrinsic capacity composite score ranges from 0 to 100, and the higher the score, the better the outcome.	An average of 1 to 2 years
Intrinsic capacity	Intrinsic capacity is assessed by the integrated care for older people (ICOPE) scale. The minimum value of the ICOPE score is 0, and the maximum value is 5, the higher the score, the better the outcome.	An average of 1 to 2 years
Frailty	Frailty is assessed using the Fried frailty phenotype (FFP) scale. The minimum value is 0, and the maximum value is 5. The higher the score, the worse the outcome.	An average of 1 to 2 years
Hospitalization	Hospitalized times, duration, diagnosis, surgery, bedridden status, assisted ventilation treatment, catheter treatment are collected by questionnaire and supplemented through a review of electronic medical records.	An average of 1 to 2 years
Death	The date and cause of death are collected from the participant's family members/healthcare providers and supplemented through a review of electronic medical records.	An average of 1 to 2 years
Appendicular skeletal muscle mass	Appendicular skeletal muscle mass (ASM) is estimated using a physical measurement formula. Weight in kilograms, height in centimeters, gender(male or female), and age in years are combined to report ASM through the formula: ASM = 0.193*weight(kg) + 0.107*height(cm) - 4.157 * gender - 0.037*age(year) - 2.631. The higher the value, the better the outcome.	An average of 1 to 2 years
Muscle strength	Muscle strength is assessed by the grip strength. The higher the value, the better the outcome.	An average of 1 to 2 years
Physical performance	Physical performance is assessed by the Short Physical Performance Battery (SPPB) test. The minimum score is 0, and the maximum score is 12. The higher the score, the better the outcome.	An average of 1 to 2 years
Sarcopenia	Sarcopenia is screened by the SARC-F scale. The minimum value is 0, and the maximum value is 10. The higher the score, the worse the outcome.	An average of 1 to 2 years
Sarcopenia	Sarcopenia is assessed based on the criteria recommended by the Asian Working Group for Sarcopenia (AWGS) 2019 consensus, including muscle strength, plus appendicular skeletal muscle mass (ASM), and/or physical performance. AWGS 2019 contends that diagnosing sarcopenia requires both low muscle strength and muscle mass, and defines persons with low muscle mass, low muscle strength, and low physical performance as having "severe sarcopenia."	An average of 1 to 2 years

Collaborators and Investigators

• Sponsor: Xuanwu Hospital, Beijing
• Collaborators: Beijing Municipal Health Commission
• Investigators: Principal Investigator: Yansu Guo, Ph.D, Beijing Geriatric Healthcare and Disease Prevention Center, Xuanwu Hospital, Capital Medical University

Study record dates

Study Major Dates

• Study Start (Actual): August 7, 2023
• Primary Completion (Estimated): July 31, 2028
• Study Completion (Estimated): July 31, 2028

Study Registration Dates

• First Submitted: February 16, 2025
• First Submitted That Met QC Criteria: March 3, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 3, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Ageing; Cognitive Impairment; Cohort; Disability; Community
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Neurocognitive Disorders; Cognition Disorders; Frailty; Cognitive Dysfunction
• Other Study ID Numbers: No.[2023]129; 2024-2G-20112 (Other Grant/Funding Number: Capital's Funds for Health Improvement and Research)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No